News

The National Hemophilia Foundation will be holding our quarterly Board of Directors meeting on Thursday, May 28th at 7:00 PM EDT. The Board…

Dear Community Members, The National Hemophilia Foundation wishes to inspire and partner with the community on their journeys to a cure and…

UniQure N.V., a gene therapy company advancing transformative therapies for patients with severe medical needs, reported recent progress across its business. “Despite…

Pfizer Inc. and BionTech SE announced the first participants have been dosed in the U.S. in the Phase 1/2 clinical trial for…

Findings from an international study published in the journal Medicine suggest that the visible presence of blood in urine (macroscopic hematuria) could represent increased…

Dear Community Members, The National Hemophilia Foundation’s priority has always been the health and safety of the bleeding disorders community. As the…

The National Hemophilia Foundation (NHF) and Hemophilia Federation of America (HFA) are seeking comments from the bleeding disorders community on the executive summary…

Genentech recently distributed a notice relevant to its product Hemlibra®, reminding health care providers that it is known to interfere with certain laboratory assays used to…

BD is conducting a voluntary medical device recall for multiple lots of the BD PosiFlush™ SF (Sterile Field) Saline Flush Syringe 10mL identified…

The Centers for Disease Control and Prevention (CDC) are currently soliciting written comments on pain and pain management, including those relevant to…

BD is conducting a voluntary medical device recall for multiple lots of the BD PosiFlush™ SF (Sterile Field) Saline Flush Syringe 10mL identified…

The National Hemophilia Foundation (NHF)  is seeking comments on draft ASH, ISTH, NHF and WHF clinical practice guidelines on VWD Diagnosis &…

The National Hemophilia Foundation’s (NHF’s) Medical and Scientific Advisory Council (MASAC) issued four new documents, which were adopted by NHF’s Board of…

Novo Nordisk recently announced that they have “paused” three clinical trials for their investigational subcutaneous therapy concizumab. The therapy is developed using…

As previously reported by HFA and NHF, Takeda announced the recall of two lots of VONVENDI von Willebrand factor (recombinant) 1,300 I.U….

Aptevo Theraoeutics has sold their recombinant factor IX product IXINITY® to Canada-based Medexus Pharmaceuticals. IXINITY®, which first received approval from the U.S….

The Partners in Bleeding Disorders Education Program has announced the launch a new version of “Understanding Hemophilia,” a six-part online learning activity for clinicians…

It is critical that an individual with a bleeding disorder who presents in an emergency department (ED) be triaged and administered care…

The National Hemophilia Foundation (NHF) has been monitoring the latest information on the current coronavirus (2019-nCoV) as it pertains to the bleeding…

Novo Nordisk has announced the launch of ESPEROCT®, the company’s long-acting recombinant factor VIII product for the prevention and treatment of bleeding…

An important new educational activity has launched for healthcare providers who practice in an emergency department setting. “Evaluation and Management of Hemophilia…

The U.S. Food and Drug Administration (FDA) has released several new gene therapy guidance documents to provide “regulatory clarity” for developers of…

Washington, D.C.—January 15, 2020— Patient and health advocacy groups representing millions of Americans with pre-existing conditions will file an amicus curiae or friend of the…

Please join us at NHF’s Bleeding Disorders Conference, August 6-8, 2020 in Atlanta, Georgia. Registration is now open! New this year! We…